Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics (Q43190965)

15 November 2017

title

Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics (English)

1 reference

15 November 2017

0 references

0 references

1

Christopher A Ross

1 reference

15 November 2017

2

Ira Shoulson

1 reference

15 November 2017

publication date

1 December 2009

1 reference

Parkinsonism and Related Disorders

15 November 2017

published in

1 reference

15 November 2017

volume

15 Suppl 3

1 reference

15 November 2017

page(s)

S135-8

1 reference

Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG).

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Preparing for preventive clinical trials: the Predict-HD study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Onset and rate of striatal atrophy in preclinical Huntington disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Regional cortical thinning in preclinical Huntington disease and its relationship to cognition

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

In vivo evidence for the selective subcortical degeneration in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Functional brain changes in presymptomatic Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Functional imaging in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Is brain lactate increased in Huntington's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Genetics of Parkinson's disease and parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Gene-environment interactions in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Replicating Huntington's disease phenotype in experimental animals

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Huntington's disease: the challenge for cell biologists

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Huntington's disease: from pathology and genetics to potential therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Huntington's disease: seeing the pathogenic process through a genetic lens

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Drug targeting of dysregulated transcription in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Paroxetine retards disease onset and progression in Huntingtin mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970800-4

7 January 2021

10.1016/S1353-8020(09)70800-4

Identifiers

DOI

1 reference

15 November 2017

1 reference